**QIBA FDG-PET Biomarker Committee (BC) Call**  
**02 March 2018 at 9 AM CT**  
**Call Summary**

**In attendance:**  
- **RSNA**  
  - John Sunderland, PhD (Co-Chair)  
  - Cris Crisman, MBA  
  - Anne Smith, PhD  
  - Joe Koudelik  

- **Rathan Subramaniam, MD, PhD, MPH (Co-Chair)**  
  - Martin Lodge, PhD  
  - Timothy Turkington, PhD  
  - Julie Lisiecki  

- **Scott Wollenweber, PhD (Co-Chair)**  
  - Nancy Obuchowski, PhD  
  - Richard Wahl, MD, FACR  

- **Ronald Boellaard, PhD**  
  - Amy Perkins, PhD  
  - Jeffrey Yap, PhD  
  - Nancy Obuchowski, PhD  

**Moderator:** Dr. Sunderland

**Status of Recruitment for PET/MRI Task Force**

- 53 people are currently signed up for the PET/MRI Task Force to modify the existing QIBA FDG-PET/CT Profile
- A champion in the field is needed to lead this task force
  - Dr. Sunderland nominated Dr. LaForest, who is presently running a PET/MRI test-re-test clinical trial
  - Dr. Sunderland to follow up with Dr. LaForest to invite him to take on this role
  - Dr. Sunderland also intends to contact Dr. Smith for suggestions for participants from Siemens
  - Dr. Wollenweber mentioned Dr. Tim Deller as a possible co-chair from industry
  - Dr. Boellaard volunteered to help with the effort, but not in a leadership role
- Dr. Sunderland will draft an email to volunteers for the PET-MRI Task Force to update them on plans

**Dashboard**

- Dr. Sunderland indicated that the FDG-PET BC co-chairs will assist Dr. Kinahan with updating the QIBA NM dashboard

**Claim Confirmed Clinical Trial Efforts**

- The application for ACR Foundation funding ($275,000) was submitted on February 25th
- While the BC waits to hear back from ACR, efforts to refine the imaging protocol continue
- Need to determine what inclusion criteria will be associated with the study, e.g. what types of cancer, anatomic locations, etc.
- Minimum and maximum numbers for lesions are also needed
  - A maximum number of lesions per patient must be decided upon to prevent bias
  - Need to resolve if there will be a limit to anatomic locations
  - Want to make certain that organs are not over- or under-represented
- An estimated number of appropriate frames with different sphere sizes should be selected that would demonstrate good variability
- May also want to monitor the injection sites for FDG to evaluate what impact the injection sites may have on SUV measurements

**Site requirements**

- There will be 100 evaluable scans and financial support for Dr. Obuchowski and 3 readers
- Eight ECOG-ACRIN sites have expressed interest in participating in the trial if funding is approved
- Caution voiced that studies should not be limited to ECOG-ACRIN sites
- ECOG-ACRIN would send follow up site surveys regarding proposed trials
- Dr. Wahl asked how sites would be monitored to ensure adherence to quantitative protocols
  - Criteria will be needed to qualify participating sites as adhering to the QIBA FDG-PET/CT Profile
Dr. Sunderland noted that QIBA oversight is critical for the protocol design as there are many secondary items the team wants to verify through the trial.

Round-6 Funded Projects Wrap Up:
- Dr. Turkington presented an overview of his Round-6 project findings on measuring variability and how it can be estimated across algorithms.
- Dr. Subramaniam will present a summary slide of his Round-5 project on the next BC call, April 6th.

Action Items for Next Call:
- Dr. Kinahan to circulate updated proposed paper for Radiology for review and comment by the BC co-chairs.
- Dr. Sunderland to invite Dr. LaForest to lead the PET-MRI Profile task force.
- Dr. Wollenweber to invite Dr. Deller to the PET-MRI Profile task force.
- The next call will focus on more in-depth study design for the clinical trial.
- RSNA staff will provide FDG-PET BC co-chairs a list of nuclear medicine QIBA members attending the 2018 Annual Meeting.

Nuclear Medicine WebEx Schedule:

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/09</td>
<td>PET Amyloid BC</td>
</tr>
<tr>
<td>03/16</td>
<td>SPECT BC (TBD)</td>
</tr>
<tr>
<td>03/23</td>
<td>NM Coordinating Ctte CC</td>
</tr>
<tr>
<td>04/06</td>
<td>FDG-PET BC</td>
</tr>
<tr>
<td>04/13</td>
<td>PET Amyloid BC</td>
</tr>
<tr>
<td>04/20</td>
<td>SPECT BC (TBD)</td>
</tr>
</tbody>
</table>

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.